v3.26.1
Collaborative Agreements (Details) - USD ($)
$ / shares in Units, shares in Thousands
6 Months Ended 12 Months Ended
Jun. 18, 2024
May 23, 2024
May 14, 2024
May 08, 2024
Apr. 16, 2024
Mar. 25, 2024
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2024
Collaborative Agreements [Line Items]                  
Licensing fee           $ 33,500,000      
Milestone regulatory payment amount $ 3,500,000         $ 3,500,000      
Percentage of royalties of net sales           5.00%      
Cash receipt              
Cash and recognized revenue                 $ 296,000
Number of shares received (in Shares)   1,250 1,250       1,250    
Cash receipt              
Collaborative agreement with ForSeeCon Eye Corporation [Member]                  
Collaborative Agreements [Line Items]                  
Upfront payment           $ 30,000,000      
Number of shares paid of licensing agreement (in Shares)           5,000      
FEYE stock (in Dollars per share)           $ 6      
Shares received (in Shares)             5,000    
OncoX BioPharma, Inc., [Member]                  
Collaborative Agreements [Line Items]                  
Consideration paid   $ 6,250,000 $ 6,250,000 $ 6,250,000 $ 6,250,000        
Shares issued (in Shares)   1,250 1,250 1,250 1,250        
Price per share (in Dollars per share)   $ 5 $ 5 $ 5 $ 5        
Additional milestone payment in cash   $ 625,000 $ 625,000 $ 625,000 $ 625,000        
Royalty percentage   5.00% 5.00% 5.00% 5.00%        
Number of shares received (in Shares)             1,250    
Percentage of develop and commercialize   50.00% 50.00% 50.00%          
Licensing fees   $ 100,000 $ 100,000 $ 100,000          
Cash Received and revenue recognized                 $ 200,000
ForSeeCon Eye Corporation [Member]                  
Collaborative Agreements [Line Items]                  
Licensing agreement $ 100,000